RT Journal Article
SR Electronic
T1 Prognostic value of promoter hypermethylation of tumor suppressor genes in malignant pleural fluid
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p3544
VO 38
IS Suppl 55
A1 Maribel Botana-Rial
A1 Loreta de Chiara
A1 Virginia Leiro-Fernández
A1 Diana Valverde
A1 Cristina Represas- Represas
A1 Ana Isabel González-Silva
A1 Alberto Fernández-Villar
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p3544.abstract
AB Background: To determine the prognostic value of promoter hypermethylation of p16/INK4a, MGMT, BRCA1 and RAR β genes in pleural fluid (PF) and other clinicopathological parameters in malignant pleural effusion (MPE).Methods: We evaluated 49 patients.We recorded clinical characteristics, characteristics of the PF, the detection of promotor hypermethylation of the tumor suppressor genes in PF by methylation-specific polymerase chain reaction.Results: We inclued 37 (75.5%) lung cancer patients and 12 (24.6%) with others epithelial neoplasias.The median time of global survival was of 255.5 (IC 95%:56-488.5) days.Parameters associated with a minor survival were: the presence of others metastasis (p=0.003); no chemotherapy treatment (p=0.001); pH<7.28 (p=0.004); glucose<60 (p=0.002) and the absence of some methylated gene (p=0.003).After the multivariate analysis, chemotherapy treated have a significantly reduced risk of death (OR=0.05;p = 0.001).Patients with metastasis (OR = 5.1;p=0,001) and patients with pH <7.28 (OR=3.2;p=0.03) have more risk of death.Chemotherapy treatment received (OR=0.1;p=0.001) and the presence of methylated genes (OR=0.2;p=0.02) were factors associated with major survival in patients with lung adenocarcinoma diagnosis.Conclusions: In patients with lung adenocarcinoma, the presence of promotor hypermethilation of genes and history of chemotherapy treatment were significantly associated with major survival.Tumor extension, not having received chemotherapy and the caracteristics of the PF were factors related to the risk of death in all MPE patients analyzed.FIS-FEDER PI081100, Conselleria de Sanidade PS08/18, SOGAPAR 2007, Intensification activity from FIS